<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Hyperlipidemia in Patients with Calcific Tendinitis

dc.contributor.authorİnanç, İbrahim Halil
dc.contributor.authorPolat, Esra
dc.contributor.authorYüce, Elif İlkay
dc.contributor.authorÖzyer, Fatih
dc.date.accessioned2026-10-09T21:19:02Z
dc.date.issued2022
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractObjective: Calcific tendinitis is a disease of unclear etiology and is associated with metabolic diseases. Hyperlipidemia, one of the metabolic diseases with systemic effects, may be associated with tendinopathy and tendinitis. In this study, we aimed to evaluate the relationship between hyperlipidemia and hyper trigl yceri demia , calcific tendinitis, the location of tendinitis, and the frequency of severely symptomatic tendinitis attacks. Methods: This retrospective study included a total of 2055 patients diagnosed with calcific tendinitis between August 1, 2019, and August 1, 2021. The patients were evaluated in terms of their hyperlipidemia and hypertriglyceridemia status, statin and/or fibrate use, and the frequency of tendinitis, and the location of attack. Results: It was observed that 64.4% (n = 230) of the patients had hyperlipidemia and 11.8% (n = 42) had hyper trigl yceri demia . It was determined that the most common tendinitis area among 357 patients was the shoulder. There was no statistically significant difference between the frequency of attacks (P = .712), and the location of attack (P = .069) in patients with hyperlipidemia. There was no statistically significant difference between the frequency of attacks (P = .735) and the location of attack (P = .286) in patients with hyper trigl yceri demia . However, a statistically significant difference was found between the attack area (P = .032) in patients with triglyceride values higher than the target recommended values. Conclusion: The frequency of hyperlipidemia is high in patients with calcific tendinitis; it will be useful to evaluate patients with calcific tendinitis in terms of hyperlipidemia.
dc.identifier.doi10.5152/EurJTher.2022.22040
dc.identifier.endpage170
dc.identifier.issn2564-7784
dc.identifier.issn2564-7040
dc.identifier.issue3
dc.identifier.startpage166
dc.identifier.trdizinid1131581
dc.identifier.urihttps://doi.org/10.5152/EurJTher.2022.22040
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1131581
dc.identifier.urihttps://hdl.handle.net/20.500.12794/1127
dc.identifier.volume28
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofEuropean Journal of Therapeutics
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260922
dc.subjectGenel ve Dahili Tıp
dc.subjectKimya
dc.subjectTıbbi
dc.subjectKalp ve Kalp Damar Sistemi
dc.titleHyperlipidemia in Patients with Calcific Tendinitis
dc.typeArticle

Files